Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed, 16 citations in OpenAlex.

1. Leukaemic stem cell burden enhances prognostic precision in the non-adverse European LeukemiaNet risk group of acute myeloid leukaemia.British journal of haematology · 2026
   Article
2. Refined detection of CD34⁺CD38⁻CD45RA⁺ leukemic stem cells using a single-tube flow cytometry assay and its strong association with measurable residual disease in acute myeloid leukemia: a retrospective cohort study.Stem cell research & therapy · 2026
   Article
3. LSC-like Phenotypes Aid in the Prognosis of Adult and Elderly Acute Myeloid Leukemia Patients at a Resource-Limited Health Center.Cancers · 2026
   Article
4. Immunophenotypic abnormality quantification refines multiparameter flow cytometry-based measurable residual disease testing in adults allografted for acute myeloid leukemia in morphologic remission.HemaSphere · 2026
   Article
5. Different features of acute myeloid leukemia stem cell quantification in intensively treated patients.Haematologica · 2025
   Article
6. Leukemia stem cells for relapse prediction in AML patients receiving allografts: long-term follow-up of a prospective study.Bone marrow transplantation · 2025
   Article
7. Standardization of Measurable Residual Disease in Acute Myeloid Leukemia by Flow Cytometry: A Multicenter Study.EJHaem · 2025
   Article
8. CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents.Leukemia · 2025
   Article
9. Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia.Cells · 2025
   Review
10. Flow cytometric detection of leukemic stem cells in Acute Myeloid Leukemia: current status and future directions.Frontiers in pharmacology · 2025
    Review
11. Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR.Leukemia · 2024
    Article
12. Perspective on measurable residual disease testing in acute myeloid leukemia.Leukemia · 2024
    Review
13. Understanding differential technologies for detection of MRD and how to incorporate into clinical practice.Hematology. American Society of Hematology. Education Program · 2023
    Article
14. Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia.Cancers · 2023
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

30 authors at 15 institutions in 8 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as